Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.37 |
| ▸ | RAF1 | P04049 | 4/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065944 | 0.91 | MAPK14 (0.43) | PTGESCYP2C9MAPK14KMT2ATEK | |
| SCHEMBL3993149 | 0.80 | MAPK14 (0.43) | MAPK14TEKGUSBMAPK13RAF1 | |
| SCHEMBL4071589 | 0.78 | MAPK14 (0.46) | MAPK14KMT2AMAPK13RAF1MAPK12 | |
| SCHEMBL11633700 | 0.75 | MAPK14 (0.57) | CYP2C9MAPK14KMT2ATEKMAPK13 | |
| SCHEMBL3993152 | 0.73 | MAPK14 (0.45) | PTGESCYP2C9MAPK14KMT2AMAPK13 | |
| SCHEMBL3989284 | 0.73 | MAPK14 (0.43) | PTGESCYP2C9MAPK14TEKMAPK13 | |
| SCHEMBL4558663 | 0.73 | MAPK14 (0.46) | MAPK14TEKGUSBMAPK13RAF1 | |
| SCHEMBL5613105 | 0.72 | MAPK13 (0.59) | MAPK14TEKMAPK13RAF1MAPK12 | |
| SCHEMBL4413641 | 0.70 | MAPK14 (0.70) | MAPK14TEKMAPK13RAF1MAPK12 | |
| SCHEMBL8479656 | 0.69 | PTGES (0.48) | PTGESCYP2C9MAPK14KMT2ATEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | PTGES 3473/4885CYP2C9 3008/4885MAPK14 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.